Racial, ethnic disparities explored in subjective cognitive decline
More Black and Hispanic adults than white adults report subjective cognitive decline at age 45 to 54 years.
Alzheimer’s
A very troubling $56 billion question
Considering some of the alternatives, I’m far from convinced that bankrupting Medicare for the sake of Aduhelm would be money well spent.
Senior living community trains first responders to ‘take it down a notch’ through dementia education
After witnessing a troubled interaction between a young police officer and a man with dementia, one senior living community offered to train first responders on communication techniques to increase successful interactions.
Changes in movement may indicate preclinical Alzheimer’s disease
Changes in daytime fractal motor activity regulation may occur in women before cognitive symptoms of Alzheimer’s disease.
House committees to investigate new Alzheimer’s disease drug approval
The FDA approved aducanumab earlier this month, despite advisory committee’s conclusion that there was not enough evidence to support its effectiveness.
Prediction model for brain age may help detect cognitive decline
Greater differences between predicted age based on brain MRI and actual age were seen in those with amnestic mild cognitive impairment versus healthy controls.
More news for Monday, June 28
DA reverses plans to seek death penalty for alleged senior living serial killer … FDA grants breakthrough therapy designation to donanemab and lecanemab for Alzheimer’s … Vapors from alcohol-based hand sanitizers can have side effects, FDA warns … Seattle senior living community scrambles for air conditioners during rare heatwave … House passes bill to make age-discrimination cases easier to prove … New affordable housing community for LGBTQ+ seniors said to be first in Texas, largest in U.S.
Lilly to seek FDA approval for new drug for Alzheimer’s disease
Donanemab already has received a ‘breakthrough therapy’ designation from the FDA.
Florida increases state funding for Alzheimer’s disease to $51 million
Florida is increasing its funding for Alzheimer’s and dementia funding by more than $12 million, bringing the state’s total commitment to more than $51 million for the 2021-2022 fiscal year.
3 FDA advisory panel members resign in wake of controversial approval of new Alzheimer’s drug
Three members of a Food & Drug Administration advisory panel resigned this week over the agency’s controversial decision on Monday to approve a novel therapy for Alzheimer’s disease.
Next post in News
